Susquehanna Fundamental Investments’s PTC Therapeutics PTCT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-21,887	Closed	-$1.07M	–	723
2025 Q2	$1.07M	Sell	21,887 -13,941	-39%	-$662K	0.03%	437
2025 Q1	$1.83M	Buy	35,828 +4,158	+13%	+$207K	0.03%	547
2024 Q4	$1.43M	Buy	+31,670	New	+$1.36M	0.02%	617
2023 Q2	–	Sell	-91,468	Closed	-$4.43M	–	827
2023 Q1	$4.43M	Sell	91,468 -29,351	-24%	-$1.34M	0.1%	243
2022 Q4	$4.61M	Sell	120,819 -5,669	-4%	-$236K	0.08%	313
2022 Q3	$6.35M	Buy	+126,488	New	+$6.2M	0.11%	259
2022 Q1	$1.31M	Buy	+35,020	New	+$1.35M	0.03%	731

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Fundamental Investments's PTCT Position: Q3 2025 in Review

Susquehanna Fundamental Investments sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 21,887 shares — an estimated $1.07M sold.

Susquehanna Fundamental Investments first reported a position in PTCT in Q1 2022 and held it in 7 quarters. The position peaked at $6.35M in Q3 2022. 294 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

Susquehanna Fundamental Investments reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 21,887 PTC Therapeutics shares in Q3 2025, an estimated $1.07M.
Susquehanna Fundamental Investments first reported a position in PTC Therapeutics in Q1 2022 and held it in 7 quarters.
Susquehanna Fundamental Investments's PTC Therapeutics position peaked at $6.35M in Q3 2022.
294 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2025, filed 14 Nov 2025.